

Supplemental Table S9. Allele Frequencies of HLA-DPB1 in Patients with ICI-T1DM

Allele	ICI-T1DM (<i>n</i> =14)					ICI-controls (<i>n</i> =26)			Controls (<i>n</i> =1,483) ^a	ICI-T1DM vs. ICI-controls				ICI-controls vs. controls
	Number	F, %	<i>P</i> value ^b	OR	95% CI	Number	F, %	<i>P</i> value ^b	F, %	<i>P</i> value ^b	OR	95% CI	<i>P</i> value ^b	
DPB1*02:01	1	7.1	NS			6	23.1	NS	24.11	NS			NS	
DPB1*02:02	0	0.0	NS			2	7.7	NS	3.41	NS			NS	
DPB1*03:01	0	0.0	NS			4	15.4	NS	3.98	NS			NS	
DPB1*04:01	0	0.0	NS			2	7.7	NS	5.06	NS			NS	
DPB1*04:02	1	7.1	NS			3	11.5	NS	9.78	NS			NS	
DPB1*05:01	11	78.6	0.0075 ^c	5.98	1.57–22.82	7	26.9	NS	38.40	0.0027 ^c	9.95	2.13–46.56	NS	
DPB1*09:01	0	0.0	NS			0	0.0	NS	9.95	NS			NS	
DPB1*13:01	0	0.0	NS			1	3.8	NS	1.96	NS			NS	
DPB1*14:01	0	0.0	NS			1	3.8	NS	1.48	NS			NS	
DPB1*19:01	1	7.1	NS			0	0.0	NS	0.74	NS			NS	
Others	0	0.0	NS			0	0.0	NS	1.13	NS			NS	
Total	14	100.00	0.0075			26	72.22		100.00					

Alleles with frequencies more than 1.0% in controls were included to the analysis (10 alleles).

HLA-DPB1, human leukocyte antigen DPB1; ICI-T1DM, immune-checkpoint inhibitor-induced type 1 diabetes mellitus; F, frequency of the allele; OR, odds ratio; CI, confidence interval; NS, not significant.

^aControl subjects: Japanese Society for Histocompatibility and Immunogenetics (<http://jshi.umin.ac.jp/standardization/file/JSHI-hyokiallele-2021list.pdf>) (JSHI2021) [16]; ^bThe association of haplotype frequencies with each disease was analyzed using Fisher's exact test with 2×2 contingency tables; ^c*P* values less than 0.05.